Stockscreener 앱 받기
39.57
2.59%
1.00
전일 마감가:
$38.57
열려 있는:
$39.21
하루 거래량:
1.24M
Relative Volume:
1.24
시가총액:
$8.55B
수익:
$1.97B
순이익/손실:
$92.93M
주가수익비율:
97.32
EPS:
0.4066
순현금흐름:
$459.60M
1주 성능:
-0.75%
1개월 성능:
-19.01%
6개월 성능:
-18.25%
1년 성능:
-10.26%
1일 변동 폭
$38.80
$39.59
1주일 범위
$38.49
$40.21
52주 변동 폭
$38.49
$49.30
Qiagen Nv Stock (QGEN) Company Profile
QGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
39.57 | 8.55B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
Qiagen, Bio-Techne downgraded at Baird amid NIH funding concerns - MSN
QIAGEN NV : Berenberg remains its Buy rating -February 21, 2025 at 03:41 am EST - Marketscreener.com
Baird Downgrades Qiagen N.V. (BIT:1QGEN) - Nasdaq
Baird Downgrades Qiagen N.V. (QGEN) - MSN
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034 - GlobeNewswire Inc.
Baird Downgrades Qiagen N.V. (BRSE:QGEN) - Nasdaq
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Baird Downgrades Qiagen N.V. (LSE:0RLT) - Nasdaq
Qiagen downgraded to Neutral from Outperform at Baird - TipRanks
QIAGEN opens new data center in Melbourne - MSN
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials Driving The Negative Sentiment? - Simply Wall St
Institutional owners may take dramatic actions as Qiagen N.V.'s (NYSE:QGEN) recent 5.6% drop adds to one-year losses - Yahoo Finance
QIAGEN NV : Deutsche Bank keeps its Buy rating -February 14, 2025 at 07:01 am EST - Marketscreener.com
William Blair Issues Negative Forecast for Qiagen Earnings - MarketBeat
Qiagen (NYSE:QGEN) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region - br.ADVFN.com
QIAGEN opens new data center in Melbourne By Investing.com - Investing.com Nigeria
Major Bioinformatics Milestone: QIAGEN's 8th Global Data Hub Powers Asia-Pacific Healthcare Revolution - StockTitan
Companion Diagnostics Market Trends 2019-2024 and Forecast to 2034 - GlobeNewswire Inc.
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation - br.ADVFN.com
Qiagen (NYSE:QGEN) Shares Gap DownShould You Sell? - MarketBeat
Qiagen (NYSE:QGEN) Given New $48.00 Price Target at UBS Group - MarketBeat
Qiagen at low since July, Merck weakUSA cuts research -February 10, 2025 at 05:28 am EST - Marketscreener.com
Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Qiagen (NYSE:QGEN) Updates Q1 2025 Earnings Guidance - MarketBeat
Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance - MarketBeat
Qiagen Exceeds 2024 Financial Outlook with Solid Growth - TipRanks
Qiagen targets 4% CER sales growth for 2025 with key portfolio advancements - MSN
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand - MSN
QIAGEN NV : DZ Bank maintains a Buy rating -February 07, 2025 at 09:42 am EST - Marketscreener.com
Qiagen N.V. (NYSE:QGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition - Yahoo Finance
Qiagen (NYSE:QGEN) Receives $50.07 Consensus Price Target from Brokerages - MarketBeat
UBS Adjusts QIAGEN Price Target to $48 From $50, Maintains Neutral Rating -February 07, 2025 at 11:23 am EST - Marketscreener.com
QIAGEN Reports Solid Growth and Exceeds 2024 Outlook - TipRanks
Qiagen N.V. Q4 2024 Earnings Call: Strong Growth Amid Challenges - TipRanks
Wellington Management Group LLP Increases Stake in Qiagen NV - GuruFocus.com
Qiagen: Decent end to 2024 -February 06, 2025 at 09:58 am EST - Marketscreener.com
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
3.50%
자본화:
|
볼륨(24시간):